Kornimate/medical-research-clean huggingface dataset:
physical activity-based intervention in depressed patients: clinical, neurophysiological, epigenetic and metabolic correlates

Conditions: Major Depressive Disorder (MDD)

Summary: the goal of this clinical trial is to investigate the effect of a structured physical activity (pa) program on depressive symptomatology in adults with a diagnosis of major depression disorder (mdd). the study will evaluate changes in depressive symptoms and assess neurophysiological and biological modulations, including epigenetic, transcriptomic, and metabolic changes resulting from the pa intervention. the main questions it aims to answer are: * does physical activity have an impact on depressive symptoms and neurophysiological profiles in patients affected by depression? * what are the epigenetic and metabolic mechanisms through which pa can modulate the intensity of depressive symptoms? participants will be randomized into two arms: the intervention group (n total=55), in treatment with antidepressants, participating in a 12-weeks pa program; the control group (n total=55), patients in treatment with antidepressants, without receiving the pa program. all participants will be assessed at three-time points: t0 (baseline, before initiating the trial), t3 (after three months; at the end of the 12-week pa program), and t6 (6th-month follow up; three months after the pa completion). at each assessment, all participants will: * complete clinical evaluation questionnaires * provide blood samples * undergo electroencephalogram (eeg) measurements. * wear an actigraph 24 hours a day for 7 days before the initiation of the trial, at t3 and at t6). throughout the 12-week pa program, participants will keep a diary of their physical activity (minutes per day) and sleep patterns (hours per night).


Eligibility criteria:
inclusion criteria: * age \> 18 years * primary diagnosis of depression (dsm-5 criteria) * symptoms of depression according to madr, bdi, zdr scale * ability to provide written ic * self-reported moderate-intensity leisure pa\< 150 min/week exclusion criteria: * severe psychopathology * medical contraindications to pa (par-q) * orthopedic problems/diseases which limit physical fitness assessment * currently pregnant (or planning to become pregnant)

Keywords: major depressive disorder physical activity
exploratory study to investigate efficacy of las41004 in a psoriasis plaque test

Conditions: Psoriasis

Summary: the aim of the exploratory study is to compare the dose-related efficacy of las41004 in a psoriasis plaque test (ppt).


Eligibility criteria:
key inclusion criteria: * male or female patients between 18 and 75 years of age with a diagnosis of stable plaque-type psoriasis (psoriasis vulgaris) for at least 12 months * psoriatic plaques that are suitable to be defined as target area lesions by the following criteria: opsoriatic plaques must be located on the trunk and/or extremities. plaques that are located on the head (incl. scalp), palms, sole of the feet, intertriginous or genitoanal areas are not suitable as target areas * comparable psoriatic plaques with at least "2" in each score (range 0-4) for the three distinct signs: scaling, erythema and induration * no more than 3 points difference in total score (= sum of scores for scaling, erythema and induration; range 0-12) of the chosen comparable psoriatic plaques * enough surface area to the psoriatic plaque to define eight clearly distinguishable (minimum distance between test areas: 1cm) test areas of at least 1 cm² size - effective contraceptive methods for the duration of the study and for the 4 weeks after study drug discontinuation, for a patient of childbearing potential. key exclusion criteria: * too small a body surface area covered with psoriasis plaques that meet the specified inclusion criteria * any condition that may interfere with the study assessments or ultrasound measurements of the skin and/or may have an influence on the skin immune response (incl. open wounds) * current diagnosis of guttate, erythrodermic or pustular psoriasis * patients who have received any topical anti-psoriatic drug in the test area within the last 2 weeks before treatment with the imp. * patients who have received topical products in the test area containing deet (n,n-diethyl-m-polyamide), a common component of insect repellent products within 1 week before treatment with the imp. * patients who have received systemic biologics within the last 6 months before treatment with the imp or any systemic antipsoriatic treatment (corticosteroids, ciclosporin, methotrexate, fumaric acid esters, acitretin etc)within the last 3 months before treatment with the imp. * significant skin diseases other than plaque-type psoriasis (psoriasis vulgaris), including but not limited to: skin disease due to tuberculosis or syphilis, rosacea, perioral dermatitis, acne vulgaris, skin atrophy, striae distensae, increased fragility of skin blood vessels, ichthyosis, ulcers, wounds and reaction after vaccination * significant skin infections (including but not limited to: herpes, varicella, mycotic skin infections, bacterial skin infections or parasitic skin infections) * excessive sunlight exposure within 28 days prior to study entry and during the conduct of the study * usage of any topical formulation (incl. cosmetics, emollients, etc) on the designated target areas during the course of the study * vitamin a intake \> 15,000 iu/day

Keywords: ppt, topical, psoriasis
pharmacokinetics of piperacillin/tazobactam in patients treated by continuous renal replacement therapy

Conditions: Diffusive and Convective Clearance; Body Clearance; Piperacillin Tazocilline Concentrations (Cmin)

Summary: the pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration.

the pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration. this is a prospective study. continuous replacement therapy has a continuous effect on drug elimination which could compromise effective antibiotic treatment. patients will receive a standard course of pip/tazo 4g intravenously 8 hourly administrated immediately when cvvhdf will be started. blood samples will be collected at 30mn, 2h, 4h, 6h, 8h, 16h, 24h for the first and the second day. we will measure plasma piperacillin/tazobactam concentration and compare them to mics for the whole dosing interval.

Eligibility criteria:
inclusion criteria: * 18 years of age and older . * females of childbearing potential must have a negative pregnancy test at screening. * subjects whose life expectancy is estimated over 7 days. * anuric patients requiring continuous venovenous hemodiafiltration * septic patients,severe sepsis or septic shock * written informed consent should be given either by the patient or a member of his family exclusion criteria: * subjects with a history of true allergy or adverse drug reactions * pathogens whose antibiotic susceptibility is not proved. * patients having impaired hepatic function * contraindication of anticoagulation by heparin * residual renal function * participation in a clinical trial * interruption of treatment by piper/tazo or hemodiafiltration during the study. * patients with psychiatric disorder or serious medical condition which in the opinion of the investigator may lead to complexity in patient management.

Keywords: pharmacokinetics piperacillin/tazobactam. septic patients oliguric renal failure continuous veno-venous hemodiafiltration.
growth hormone therapy in liver cirrhosis

Conditions: Cirrhosis, Liver

Summary: liver cirrhosis (lc) is a leading cause of morbidity and mortality worldwide. life- threatening complications of liver cirrhosis are ascites, gastrointestinal bleeding, variceal bleed, hepatic encephalopathy and hepatocellular carcinoma (hcc) which are associated with poor prognosis.the leading causes of liver cirrhosis include excess alcohol consumption, viral hepatitis and non-alcoholic fatty liver disease. malnutrition is common in end-stage liver disease (cirrhosis) and is often associated with a poor prognosis. it occurs in all forms of cirrhosis with different etiology and prevalence ranges from 65 to 100% depending upon the methods used for nutritional assessment and the severity of liver disease. nutritional state influences survival in patients with decompensated cirrhosis. protein malnutrition manifested by reduced skeletal muscle mass and hypoalbuminemia, exist in patients with cirrhosis despite apparent adequate food consumption and these patients have a higher rate of complications and, overall, an increased mortality rate. also, malnutrition has significant implications for liver transplantation; patients with poor nutritional status before transplantation have increased complications and higher mortality rates postoperatively. screening all patients with chronic liver disease for nutritional abnormalities can identify those at risk of developing preventable complications. malnutrition is commonly associated with protein catabolism and the protein catabolic state of cirrhosis is associated with severe growth hormone (gh) resistance, with low levels of insulin-like growth factor (igf)-i and its major binding protein (igfbp)-3. gh therapy in cirrhosis has been shown to improve nitrogen economy and to improve the gh resistance in a small pilot study by donaghy et al. also, gh therapy of short duration has shown to increase igf1 levels, igfbp-3 levels in patients of cirrhosis. gh therapy has also shown to improve liver regeneration and protein synthesis after hepatectomy in patients of hcc with cirrhosis. however there is scarcity of data on clinical impact of long term administration of gh therapy in patients of cirrhosis. hence, we undertook the present study to study the effect of growth hormone on nitrogen economy, malnutrition and liver regeneration in patients with cirrhosis.


Eligibility criteria:
inclusion criteria: * decompensated cirrhosis of liver irrespective of etiology exclusion criteria: * acute on chronic liver failure (fulfilling either apasl or canonic criteria of aclf) * splenic diameter of more than 18 cm * concomitant hcc or other active malignancy * upper gastrointestinal bleeding in the previous 7 days * portal vein thrombosis * severe renal dysfunction as defined by creatnine \> 1.5mg/dl * severe cardiac dysfunction * uncontrolled diabetes (hb a 1c ≥ 9) or diabetic retinopathy * acute infection or disseminate intravascular coagulation * active alcohol abuse in last 3 months * known hypersensitivity to gh * hiv co-infection * pregnancy * refusal to give informed consent

Keywords: growth hormone cirrhosis
evaluation of the colonization capacity of a probiotic bacterium.

Conditions: Obese; Weight, Body

Summary: the goal of this interventional study is to test the colonization of a new generation probiotic in normal weight and overweight/obese people. the main question aims to answer is if our bacteria is able to colonize the human intestine. participants will recieve a probiotic pill every day during 15 consecutive days and fill in questionaries.

normal weight and overweight volunteers will be recruited to evaluate the colonization capacity of the bacteria. in this case, stool samples will be taken before starting the intervention (t0), after the treatment (t1) and a week after fiinishing the administration of the probiotic (t2). all the subjects will receive the probiotic supplement in capsules taken daily, 7-8 normal weight subjects will take a concentration of 10\^9-10 cfu and 7-8 overweight subjects will take a concentration of 10\^9-10 cfu.

Eligibility criteria:
inclusion criteria: * age between 18 and 65 years. * body mass index between 20-25 kg/m2 for normopese subjects and bmi 25-30 kg/m2 for overweight participants. * body weight and eating habits stable in the last three months before the first visit. * willingness to participate in the intervention study, giving their data and samples. * signature and acceptance of the informed consent. exclusion criteria: * preexistence of other physical conditions (food allergy/sensitivity, gastrointestinal conditions \[such as inflammatory bowel disease, celiac disease, pancreatitis, chronic constipation, etc.\], immunodeficiency) * eating disorders * use of antibiotics one month prior to the first visit * chronic use of medications (antacids, antidiabetics, anti-hypertensives, etc.) * history or current abuse of drugs or alcohol * following a vegetarian, vegan, or other restrictive diet * any other reason deemed appropriate for exclusion at the clinician's discretion * non-compliance with adherence to treatment regimen * direct association with research and/or investigators

Keywords: probiotic obese colonization microbiota
effect of high intensity exercise rehabilitation on liver function and insulin sensitivity in patients with masld

Conditions: Exercise Therapy; Metabolic Dysfunction-associated Steatotic Liver Disease

Summary: metabolic dysfunction-associated steatotic liver disease (masld) is the most common liver disease worldwide, and is associated with obesity and the metabolic syndrome. physical activity and lifestyle interventions are among the most recommended treatments for individuals with masld. in this rct, we will evaluate the effect of combined exercise training "strength and aerobic training" versus "strength and high intensity training (hiit)". the main outcome parameter is the severity of liver steatosis. patients will be recruited at the fatty liver clinic of the uz gent.

physical activity and lifestyle interventions, including exercise, are recommended for individuals with metabolic dysfunction-associated steatotic liver disease (masld). weight loss has been found to improve masld histologically, but exercise alone can also reduce liver fat accumulation, even without significant weight loss. exercise has positive effects on chronic inflammation, type 2 diabetes mellitus (t2dm), and mitochondrial function in masld patients. studies suggest that both aerobic and resistance exercise are effective in reducing fat content and liver enzyme levels in masld, and thereby generate positive effects on insulin sensitivity and cardiovascular risk. the potential of high-intensity interval training (hiit) is large in various settings, but was never explored in this population. moreover, the combination with strength training can have additional health effects which remain to be explored. all subjects are recruited in the liver steatosis outpatient clinic of the university hospital in ghent by the physicians and researchers of this study. after patient selection and obtaining informed consent, they will be screened in the rehabilitation center for cardiorespiratory fitness.

Eligibility criteria:
inclusion criteria: * diagnosed with masld by ultrasound, cap and/or biopsy * age between 18 and 75 years old * no significant liver fibrosis (fibroscan \ 7.5 and \<10, there must be absence of liver fibrosis in the biopsy) exclusion criteria: * presence of other liver diseases that may contribute to the clinical presentation in the patient * severe cardiovascular, orthopedic, physical or other illnesses that make it impossible to participate in the study's exercise rehabilitation program or where safety cannot be guaranteed * pregnancy * pharmacological treatment that directly affects masld (e.g. glp-1 analogues) * a change in medication in the last three months before the study that affects metabolic disease stability

Keywords: exercise masld liver diseases
diagnosis of prader-willi syndrome and angelman syndrome

Conditions: Mental Disorder; Fetus Disorder

Summary: in a retrospective study, data were assessed from cases regarding pws/as that underwent molecular diagnosis at the national chen-kung university hospital, tainan, taiwan, between january 2001 and december 2014.

prader-willi syndrome (pws) and angelman syndrome (as) are two distinct syndromes of developmental impairment that result from loss of the expression of imprinted genes on the q11-q13 region of chromosome 15 (15q11-q13). approximately 70%--75% of individuals affected with pws and as have an interstitial deletion of 15q11-q13. regarding the remaining individuals with pws, maternal uniparental disomy is the cause in 20% of cases, imprinting errors in 3% of cases, and chromosomal translocation in approximately 1% of cases. regarding the remaining cases of as, paternal uniparental disomy accounts for 2% of cases and mutations in the ube3a gene for 20% of cases.the pws/as critical region was examined by fluorescence in situ hybridization (fish), methylation-specific pcr (m-pcr), and methylation-specific multiplex-ligation dependent probe amplification(ms-mlpa). in a retrospective study at the national chen-kung university hospital,tainan, taiwan, data were reviewed from cases that were referred for molecular diagnosis between january 1, 2001, and december 31, 2014.

Eligibility criteria:
inclusion criteria: * individual with clinical features related to prader-willi syndrome or angelman syndrome; * fetus with suspicious deletion or duplication of chromosome 15q11.2-q13 visible by the microscope; * fetus whose mother or father has chromosomal abnormality involving 15q11.2-q13 * fetus with mosaic trisomy 15 exclusion criteria:

Keywords: m-pcr fish mlpa deletion uniparental disomy imprinting mutation
a study of anagrelide and hydroxyurea in high-risk essential thrombocythemia patients

Conditions: Thrombocythemia, Hemorrhagic

Summary: essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. platelets are small cells carried around in the blood, which help form blood clots. when patients have too many platelets, there is a risk of blood clots forming unnecessarily and excessive bleeding. the aim of this study is to gain additional information on the safety profile of anagrelide (xagrid(r)) and hydroxyurea (also known as hydroxycarbamide).


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of essential thrombocythaemia - high risk profile * previously untreated with a cytoreductive agent * females of childbearing potential must have a negative urine pregnancy test prior to entering the study and must agree to use effective birth control for the duration of the study exclusion criteria: * diagnosis of any other myeloproliferative disorder * any known cause for a secondary thrombocytosis * anti-coagulant and anti-aggregant therapies * known or suspected heart disease * left ventricular ejection fraction \< 55%
effects of cardiac telerehabilitation during covid-19 on cardiorespiratory capacities in coronary artery disease patients.

Conditions: Cardiac Disease

Summary: after an acute coronary syndrome, an adapted cardiac rehabilitation program is necessary to restore or increase physical capacities and decrease cardiovascular risk. this multidisciplinary care combines physical training sessions and therapeutic education workshops. the covid-19 pandemic imposed restrictions such as the closure of rehabilitation centres. to remedy this problem, one solution was to adapt the existing program to a remote cardiac telerehabilitation, i.e., medical and paramedical supervision of rehabilitation sessions and therapeutic patient education meetings via digital tools. recent studies have shown that it was a safe (no reported adverse effects), effective (similar gains in peak oxygen consumption compared to traditional cardiac rehabilitation and patient-adherence alternative.

the hypothesis of this study is that telerehabilitation was more effective on cardiorespiratory functions.

Eligibility criteria:
inclusion criteria: both groups: * acute coronary syndrome treated in the last 6 months * medical revascularization (angioplasty ± stenting) or surgical (coronary artery bypass) for telerehabilitation group: * internet connexion (computer or digital tablet) * equipped with an exercise bike exclusion criteria: both groups: * pulmonary hypertension * aortic pathway anomaly * uncontrolled ventricular rhythm disorders for telerehabilitation group: * important muscular deconditioning * patient requiring medical supervision in institute

Keywords: cardiac telerehabilitation acute coronary syndrome rehabilitation therapeutic rehabilitation sessions cardiorespiratory functions
a culinary intervention for bone health

Conditions: Osteoporosis, Age-Related; Osteoporosis Risk

Summary: this is a randomized, controlled pilot study to evaluate the feasibility and acceptability of a single 2-hour culinary medicine intervention for bone health among individuals with age-associated low bone mass.

this is a randomized, controlled pilot study to evaluate the feasibility and acceptability of a single 2-hour culinary medicine intervention for bone health among individuals with age-associated low bone mass. a total of 40 individuals referred to a tertiary osteoporosis centre for age-associated low bone mass will be will be recruited and randomized 1:1 to attend either: 1) a 2-hour hands-on culinary medicine program at a hospital-based teaching kitchen followed by three monthly virtual group meetings, each lasting 30 minutes and led by the facilitator of the culinary nutrition program (intervention group), or, 2) not to attend the culinary nutrition program (control group). baseline data will be collected at the time of recruitment, and both the intervention and control group will be followed for 3 months.

Eligibility criteria:
inclusion criteria: * adults referred to local tertiary osteoporosis centre for assessment of age-associated low bone mass or assessment of fracture risk * women must be postmenopausal (i.e. documented history of surgical menopause, or at least 12 months since last menstrual period), men must be age ≥45 years * self-determined ability to learn in classroom and kitchen environments and a virtual (video) learning environment * reliable access to hardware, software, and internet connection required to participate in an interactive virtual (video) conference * ability to attend local hospital-based teaching kitchen for culinary medicine intervention * willing to participate in a culinary medicine intervention and provide informed consent exclusion criteria: * complex metabolic bone disease or on dialysis for end-stage kidney disease * exclusion on the basis of other active health conditions which may present a contraindication to intake of whole and calcium-rich foods will be determined by the medical team on a case-by-case basis * deemed by research team to be unable to learn in a group classroom or kitchen environment * unable to communicate in english

Keywords: osteoporosis fracture culinary nutrition culinary medicine teaching kitchen nutrition